Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Forecast for the Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market from 2024 to 2025?
In recent times, the market size for inhibitors of the calcitonin gene-related peptide (CGRP) has experienced significant growth. The market, which is expected to rise from $2.87 billion in 2024 to $3.17 billion in 2025, boasts a compound annual growth rate (CAGR) of 10.6%. This previous growth is attributed to factors such as the escalation in research and development investments, increased approvals for new drugs, a surge in demand for non-opioid pain relievers, and an intensified focus on personalized medicine.
What Is the Projected Market Size of the Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market?
The market size for inhibitors of the calcitonin gene-related peptide (CGRP) is projected to expand rapidly in the coming years and is predicted to reach a valuation of $4.68 billion in 2029, with a compound annual growth rate (CAGR) of 10.2%. The anticipated growth during the forecast period can be ascribed to factors like the increasing incidence of migraines, a growing inclination towards preventive migraine therapies, heightened patient awareness, and increased spending in healthcare. Lofty trends during the forecast period include advancements in drug formulation technology, adoption of digital health methodologies, progress in precision medicine, and technological progress in biosimilars.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24182&type=smp
Who are the Major Competitors in the Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market Outlook?
Major companies operating in the calcitonin gene-related peptide (CGRP) inhibitors market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Bristol Myers Squibb Company, AstraZeneca plc, Novartis AG, Eli Lilly and Company, Amgen Inc., Otsuka Holdings Co. Ltd., Teva Pharmaceutical Industries Ltd., H. Lundbeck A/S, Kissei Pharmaceutical Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., Shin Nippon Biomedical Laboratories Ltd., Sosei Group Corporation, Nuvie Bio Inc., Vaxxinity Inc., Acherx LLC, AfaSci Inc.
What Is Fueling Growth in the Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market?
The growth of the calcitonin gene-related peptide (CGRP) inhibitors market is anticipated to be accelerated by the escalating incidence of migraines. Migraines are severe headaches typically characterized by throbbing pain frequently on one side of the head and often coupled with symptoms such as nausea, vomiting, and sensitivity to light and sound. The rising occurrence of migraines can largely be attributed to increased stress levels, which activate neural pathways. CGRP inhibitors serve as a beneficial tool in managing migraines, as they offer a specific preventative approach which aligns with both acute and chronic care treatments. They enhance patient welfare and daily functionality by reducing the frequency and intensity of headaches via effective CGRP receptor blockade. A report from the National Library of Medicine, a health information institution based in the US, noted in January 2023 that the worldwide migraine prevalence ranged from 14% to 15%, accounting for 4.9% of the global disease burden. Consequently, this rise in migraine occurrence is facilitating the expansion of the calcitonin gene-related peptide (CGRP) inhibitors market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24182&type=smp
Which Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market Segments Are Growing the Fastest?
The calcitonin gene-related peptide (CGRP) inhibitors market covered in this report is segmented –
1) By Type Of Inhibitor: Monoclonal Antibodies, Small Molecules, Peptides
2) By Mechanism Of Action: Anti-Calcitonin Gene-Related Peptide (CGRP) Ligand, Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonist
3) By Route of Administration: Oral, Nasal, Intravenous
4) By Treatment: Preventive Migraine Treatment, Acute Migraine Treatment
5) By End User: Hospitals, Specialty Clinics, Mail Order Pharmacies, Retail Pharmacies
Subsegments:
1) By Monoclonal Antibodies: Erenumab (Aimovig), Eptinezumab (Vyepti), Fremanezumab (Ajovy), Galcanezumab (Emgality)
2) By Small Molecules: Ubrogepant, Rimegepant, Atogepant, Zavegepant
3) By Peptides: Calcitonin Gene-Related Peptide (CGRP) Antagonist Peptides, Modified Calcitonin Gene-Related Peptide (CGRP) Analogs, Intranasal Peptide Formulations, Peptide-Based Delivery Systems
Which Industry Trends Are Shaping the Future of the Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market?
Leading businesses in the calcitonin gene-related peptide (CGRP) inhibitors market are zeroing in on the production of innovative items to secure approvals, such as CGRP receptor antagonists to enhance the effectiveness of migraine treatments. They are also aiming to broaden therapeutic indications and introduce more user-friendly administration methods like oral and intranasal formulations. A CGRP receptor antagonist is a medication that suppresses the CGRP receptor to prevent pain signals associated with migraines. For example, in April 2023, the US biotech firm AbbVie Inc. obtained approval from the U.S. Food and Drug Administration (FDA) for administering QULIPTA (atogepant) in dealing with chronic migraines in adults. QULIPTA is an orally taken CGRP receptor antagonist that functions by inhibiting CGRP receptors known to play a role in migraine development, thus helping hinder the occurrence of migraine attacks.
Access The Full Report Here:
Which Countries Are Leading the Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market?
North America was the largest region in the calcitonin gene-related peptide (CGRP) inhibitors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the calcitonin gene-related peptide (CGRP) inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/customise?id=24182&type=smp
This Report Delivers Insight On:
1. How big is the calcitonin gene-related peptide (cgrp) inhibitors market, and how is it changing globally?
2. Who are the major companies in the calcitonin gene-related peptide (cgrp) inhibitors market, and how are they performing?
3. What are the key opportunities and risks in the calcitonin gene-related peptide (cgrp) inhibitors market right now?
4. Which products or customer segments are growing the most in the calcitonin gene-related peptide (cgrp) inhibitors market?
5. What factors are helping or slowing down the growth of the calcitonin gene-related peptide (cgrp) inhibitors market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model